Journal Article

Application of the CRISPR/Cas9 System to Drug Resistance in Breast Cancer

Chen, Yinnan, Zhang, Yanmin

2018

Overview

Clinical evidence indicates that drug resistance is a great obstacle in breast cancer therapy. It renders the disease uncontrollable and causes high mortality. Multiple mechanisms contribute to the development of drug resistance, but the underlying cause is usually a shift in the genetic composition of tumor cells. It is increasingly feasible to engineer the genome with the clustered regularly interspaced short palindromic repeats (CRISPR)/associated (Cas)9 technology recently developed, which might be advantageous in overcoming drug resistance. This article discusses how the CRISPR/Cas9 system might revert resistance gene mutations and identify potential resistance targets in drug‐resistant breast cancer. In addition, the challenges that impede the clinical applicability of this technology and highlight the CRISPR/Cas9 systems are presented. The CRISPR/Cas9 system is poised to play an important role in preventing drug resistance in breast cancer therapy and will become an essential tool for personalized medicine. The application of the CRISPR/Cas9 system for editing drug resistant genes and identifying potential targets in drug resistant breast cancer is discussed. It is proposed that, with further development, the CRISPR/Cas9 system can play a more important role in preventing drug resistance in breast cancer therapy and that it will become essential in personalized and precision medicine.

• Publisher: John Wiley & Sons, Inc,John Wiley and Sons Inc,Wiley
• Subject: Apoptosis / Biosynthesis / Breast cancer / Cancer therapies / Cell cycle / Chemotherapy / Competition / CRISPR / CRISPR/Cas9 / Drug resistance / Drug therapy / Efficiency / Enzymes / Estrogens / Genes / Genetic engineering / Genomes / Kinases / Ligands / Mortality / Mutation / Proteins / reverting resistance / Review / Reviews / RNA polymerase / Signal transduction